Allarity Therapeutics up as lead drug shows clinical benefit in mid-stage trial

Allarity Therapeutics

05/12/2023 13:47

** Shares of drug developer Allarity Therapeutics  ALLR.O 
rise 61.7% to 98 cents premarket
    ** Co says its lead drug candidate Stenoparib for advanced
ovarian cancer shows clinical benefit in a mid-stage trial 
    ** Out of 5 evaluable patients, 1 experienced a complete
response while the rest experienced cancer tumor shrinkages 
    ** Up to Monday's close, stock down 99.9% YTD

 (Reporting by Puyaan Singh)
 ((Puyaan.Singh@thomsonreuters.com;))